Corresponding author
Shaw Watanabe, MD, PhD
President
Lifescience Promoting Association
25-3-1004 Daikyocho
Shinjuku-ku, Tokyo 160-0015
Japan
E-mail: watashaw@lifescience.or.jp

Basic Ketone Engine and Booster Glucose Engine for Energy Production

Shaw Watanabe, MD, PhD[1*]; Azusa Hirakawa, BS[1,2]; Seiichiro Aoe, PhD[2]; Kazunori Fukuda, MD, PhD[3]; Tetsuo Muneta, MD[4]

[1]*Lifescience Promoting Association, 25-3-1004 Daikyocho, Shinjuku-ku, Tokyo 160-0015, Japan*

[2]*Department of Food Science, Otsuma Womens' University, Chiyoda, Tokyo 102-8357, Japan*

[3]*Ginza Tokyo Clinic, Ishiwada 12 Sanbancho, Bld 5F, 14-9 Ginza 5 cho-me, Chuo-ku, Tokyo 104-0061, Japan*

[4]*Muneta Maternity Clinic, 320-7, Neda, Ichihara City, Chiba Prefecture, Japan*

ABSTRACT

Recently, hyperketonemia induced by fasting or ketogenic diet calls attention because of the possibilities for various clinical applications. Animal species comparisons and biochemical data show that all fetuses can develop by using ketogenic energy through a pathway which seems to have been maintained. We hypothesized that 3-β-hydroxybutyrate (β-HB) could be the fuel for the basic engine that produces energy in all terrestrial species. However, ATP production from glucose-pyruvic acid pathway seems to be added as a dominant system in human. We hypothesize the establishment of TCA cycle in mitochondria and enough oxygen supply since two billion years ago would be the key events to promote this change. The efficacy of ATP production from β-oxidation product is 10 ATP molecules, while it is 12.5 molecules from pyruvic acid. So, evolution should select glucose burning system as a booster engine for energy production. The liver and kidney are major ketone producing organs which contain abundant glycogen particles. So, a close relationship between ketone and glucose burning system may be present. This explains why certain level of glucose is steadily maintained even in the hyperketogenic state. Ketogenic diets efficiently treat with gestational diabetes. Placenta is the ketogenic tissue which reflects high concentration of ketones in umbilical cord blood. In addition to the role of energy source, β-HB shows various pharmacological effects on disease prevention, such as cardiovascular disease, Alzheimer's disease, epilepsy, etc. Inhibition of histone deacetylase, stimulation of FOXO, resistance to oxidative stress, protection of mitochondria, stimulation of adiponectin release, suppression of inflammasome, etc. are included. The contribution of intestinal microbiota to ketone body production should open a new field of medicine. Altogether, the above data suggest that longer-term human studies are necessary to exclude risks of unbalanced diet and to confirm the best combination of fuels for energy production, disease prevention and medical treatment.

KEYWORDS: Ketone; β-hydroxy butyrate; TCA cycle; Histon; Gestational diabetes; Fast; Endocrine; Metabolism; Pharmacology.

ABBREVIATIONS: β-HB: β-hydroxybutyrate; DKA: Diabetic ketoacidosis; ADA: American Diabetes Association; AD: Alzheimer's disease; HOMA-IR: Homeostasis model assessment of insulin resistance; SCDT: Succinyl CoA acetoacetate-CoA transferase.

DIABETIC KETOACIDOSIS

Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes which occurs in patients with either type 1 or type 2 diabetes.[1] This condition is a complex disordered metabolic state characterized by hyperglycemia, ketoacidosis, and ketonuria. Insulin deficiency leads to the release of free fatty acids from adipose tissue, hepatic fatty

Figure 1: Production of ketones and energy production.

Ketone bodies, namely acetoacetate, acetone, and 3-hydroxybutyrate (βHB) are produced during an extensive fatty acid oxidation. They are the products of acetoacetyl-CoA and acetyl-CoA condensation. Rate limiting step of ketogenesis is the formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) and is catalyzed by mitochondrial HMG-CoA syntetase (HMGCS2).

Utilization of ketone bodies as a source of energy, 3-oxoacetyl-CoA thiolase, and betaHD dehydrogenase are necessary. For degradation, succinyl-Co-A: acetoacetate-CoA transferase (SCOP) , also known as 3-oxoacid-CoA transferase is necessary. All of these enzymes are present in peripheral tissues at various levels, but SCOT is absent in the liver.

acid oxidation, and the formation of ketone bodies, such as acetoacetate, 3-β-hydroxybutyrate (β-HB) and acetone (Figure 1). The observed pro-inflammatory and pro-coagulant states in hyperglycemic crises and hypoglycemia may be the result of adaptive responses to acute stress, and not hyperglycaemia or hypoglycaemia *per se*.[1]

Usually, ketones are dealt with a risk factor of worse prognosis by ADA and other diabetes supporting organization.

FASTING AND HYPERKETONEMIA

In the fasted state, glycolysis is diminished; the flow of substrates entering the citric acid cycle drops, and ketone production are turned on. Cahill[2,3] studied the glucose metabolism of people who let themselves fast for 40 days. He reported that in the starving human adult, β-HB and aceto-acetate are produced in the liver from long-chain fatty acids and β-HB could be the energy source in the brain and other tissues. A rise of β-HB blood concentration to approximately 6 mM was characteristic. The estimated glucose production at 5-6 wk of starvation was reduced to approximately 86 g/24 hr. Of this amount the liver contributes about one-half and the kidney the remainder. Approximately all of the lactate, pyruvate, glycerol, and amino acid carbons which are removed by the liver and kidney are converted into glucose, as evidenced by substrate balances across these organs.

Cahill's research was integrative rather than reductionism, but he opened the unique insight on the metabolic adaptation of humans to starvation. During starvation, extremely low insulin levels facilitate acyl-CoA entry into mitochondria, producing excess amounts of acetyl-CoA that

cannot be metabolized in the Krebs cycle and are diverted towards the synthesis of ketone bodies (Figure 1).[4] In 1960s, it was widely held that the brain did not oxidize ketone bodies for the production of energy. Cahill was one of the few clinical investigators at that time who believed that during starvation there was not enough nitrogen in the urine to account for the alleged amount of glucose that the brain was thought to need for normal function.[5] Glucose, β-HB, and acetoacetate appeared to be used for energy sources of the brain of these people, as only ketone bodies increased without symptoms of ketoacidosis.[5]

The tissues that produce β-HB include the liver, kidney and the brain astrocytes.[6] As the brain consumes about 20% of its energy from glucose, similar amounts of ketones should be substituted to glucose to keep the brain functioning in the fasting state (Figure 2).

Koda's fasting and dietary therapy has proven effective for many intractable diseases in Japan.[7] In an extreme case the blood concentration of β-HB remained above 3 mM without any clinical and laboratory symptoms.[8] So, β-HB can substitute glucose as an energy source. It seems to stimulate the human nervous and endocrine systems, and to increase self-healing ability.

GESTATIONAL DIABETES

Gestational diabetes is not a rare complication of pregnancy. During pregnancy, the placenta produces high levels of various hormones. Almost all of them impair the action of insulin in maternal cells, raising the blood sugar level. Controlling the blood glucose can prevent birth complications and keep the

Figure 2: Glucose and ketone formation at fast or severe carbohydrate restriction. Hepatocytes, renal tubular cells and intestinal epithelial cells and astrocytes are able to carry out ketogenesis in prolonged fasting and ketogenic diets. After glucose is provided by gluconeogenesis in the liver and kidney (red arrow), ketone formation substituted (yellow). Astrocyte is considered to produce ketones up to 20% to support brain function.

baby healthy, so insulin therapy is usually tried in gestational diabetes.[9]

As the fetus grows, the placenta produces more and more insulin-blocking hormones. In gestational diabetes, placental hormones induce a rise in blood glucose up to a level that can affect the growth and welfare of the baby. Gestational diabetes is particularly severe in obese pregnant women. In such cases, insulin therapy is often ineffective, and doctors recommend abortion if elevated blood glucose levels fail to be under control.

American Diabetes Association (ADA) does not recommend a very low-carbohydrate diet where the uptake of carbohydrate is lower than 130 g per day. Muneta et al[9] recently reported the cases of 16 gestational diabetic patients who had normal deliveries after a very low-carbohydrate diet (less than 5 g per diet). The blood level of ketone bodies and free fatty acids increased consistently, with a respiratory quotient (CO_2 eliminated/O_2 consumed) of 0.72, which means main energy comes from ketone bodies under eucaloric condition.[10]

Most patients were obese and lost body weight with the MEC ketogenic diet (100 g each of meat, eggs, cheese and leaves of green-yellow vegetables), blood glucose levels returned within normal range within a few weeks, and all deliveries were under control.

Maternal starvation in late gestation lowers insulin, and lipolysis supervenes. The continued glucose drain by the conceptus aids in converting the maternal liver to the ketogenic organ, and ketone bodies produced from incoming fatty acids cross the placenta to be utilized by the fetus. Muneta[11] found high β-HB level (1 to 8 mM) among mothers, or in the umbilical cord blood, and also in the placental tissue fluid (Table 1).

High β-HB levels in the placenta have occasionally been reported by veterinarians, but most of them deals with domestic animals, where ketonemia is classically a sign of problematic delivery.[12]

DUAL ENGINE FOR ENERGY PRODUCTION

The β-HB and acetoacetate (AcAc) support mammalian survival during states of energy deficit by serving as alternative sources of ATP.[2-4] Mitochondrial 3-hydroxy-3-methylglutaryl-CoA

Material	β-hydroxybutyrate	Average	Sample number
Chorionic Villi	600~4500 uM	1930.1	98
Aborted Villi	600~3600 uM	163.2	37
Umbilical cord	300~2500 uM	779.2	60
Placental tissue	1200~5200 uM	2235	60
Peripheral blood on 4th day	100~800 uM	426.5	99
Peripheral blood at 1 month	200~700 uM	366.7	24

Table 1: Concentration of β-hydroxybutyrate of placenta and new born peripheral blood.

synthase and HMGCS2 is the rate limiting enzyme of the ketogenic pathway (Figure 1).[13-15] Succinyl CoA acetoacetate-CoA transferase (SCDT) is necessary to convert β-HB to acetoacetate in the peripheral tissue cells. SCDT is lacking in hepatic cells, so, the liver is a major ketogenic organ but cannot use it. Animal species comparisons and biochemical data show that all fetuses can develop by using ketogenic energy through a pathway which seems to have been maintained throughout evolution.[16] We thus hypothesized that β-HB could be a fuel for the basic engine that produces energy in all terrestrial species. However, ATP production from glucose-pyruvic acid pathway seems to become a dominant system in human. Why glucose has become the major fuel in the body? We hypothesize the establishment of TCA cycle in mitochondria and enough oxygen supply since 2 billion years ago would be the key reason. The efficacy of ATP production from β-oxidation product is 10 ATP molecules, while it is 12.5 molecules from pyruvic acid.[17] So, more efficient burning system has developed by using various glucose transporters in various organs throughout evolution. We may call it a booster engine for energy production. Endosymbiosis with mitochondria, which should support the burning system with oxygen, is a miracle signs of life.

The liver and kidney contain abundant glycogen particles. These organs are also ketone producing organs, so it may represent a close relationship between ketone and glucose burning system (Figure 2). This explains why certain level of glucose is steadily maintained in the blood even in the hyperketonemic person. Some people could not raise ketone levels in the blood concentration as expected even by the ketogenic diet. A metabolic homeostasis would be different in these people, and needs further study.

THERAPEUTIC USE OF KETONE DIET

Epilepsy, Autistic Behavior and Childhood Obesity

Fasting and ketogenic diet was first introduced for the treatment of epilepsy by HR Geyelin and RM Wilder's group in 1920's.[18] Over 250 medical centers worldwide offer ketogenic diets to children with epilepsy.[19] However, access to these therapies has remained extremely limited for adults until recent years.[20] From observations in 229 adults (age range of 18-86 years) attending the Adult Epilepsy Diet Center, ketogenic diet therapies appeared effective and safe in the long-term in adults.

The potential benefits of ketogenic diets are considerable. However, the effects of carbohydrate-depleted (ketogenic) diets on the metabolic parameters of children have been insufficiently assessed.[21]

To compare the efficacy and metabolic impact of ketogenic and hypocaloric diets in obese children and adolescents, fifty-eight obese subjects were assigned to one of two diets for 6 months. In both group participants significantly reduced their weight, fat mass, waist circumference, fasting insulin, and HOMA-IR, but the differences were greater in the ketogenic group. Only the ketogenic group had increasing in high molecular weight adiponectin.

Ketogenic diets may be used as a additional or alternative therapy in autistic behavior.[22]

β-HB and Prevention of Diabetic Complication

Myocardial infarction: Cardiovascular events are common in diabetic patients. After infarct by the thrombosis, resuscitated blood flow by thrombolysis often damages remained tissue. Short-term fasting reduces the extent of myocardial infarction and incidence of reperfusion arrhythmias in rats.[23] In experiments on cardiac ischemic tolerance in rats, short-term fasting increased the concentration of β-HB compared to controls. In addition, fasting limited the infarct size (48.5% of the area at risk) compared to 74.3% controls; the total number of premature ventricular complexes (12.5) was reduced compared to 194.9 controls; and the duration of ventricular tachycardia (0.6 s *vs.* 18.8 s) occurring at early reperfusion.

To investigate the role of high concentrations of β-HB in preventing heart damage after prolonged fasting, infarct size and the incidence of apoptosis caused by ischemia-reperfusion were determined in the Wistar rats.[24] Apoptosis in the sub-endocardial region was significantly reduced in fasting. In addition, the levels of ATP in the fasting DL-β-HB treated group were significantly higher compared with control groups after 30 min of ischemia and 120 min of reperfusion.

Alzheimer and other nervous disease: The Hisayama study[25] started in 1961 is a prospective cohort study characterized by all dead people being autopsied. The prevalence of all-causes, dementia and Alzheimer's disease (AD) significantly increased over time. Diabetes-related factors, such as fasting glucose, 2-hours post-load plasma glucose, fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 1988.[26] The results suggest that hyperinsulinemia and hyperglycemia caused by insulin resistance accelerate Alzheimer's disease in combination with the effects of APOE epsilon.

Excess weight, especially abdominal obesity, can cause or exacerbate cardiovascular and metabolic diseases. Obesity is also a proven risk factor for AD.

Various studies have demonstrated the beneficial effects of a ketogenic diet in weight reduction and in modifying the disease activity in neurodegenerative disorders, including AD.[3,27-30] Compared with obese rats fed a control diet, obese rats fed a ketone diet showed significant weight loss, improvements in lipid profiles and insulin resistance, and up-regulation of adiponectin mRNA expression in adipose tissues. In addition,

the ketone diet triggered significant down-regulation of the expression of brain amyloid protein precursor, apolipoprotein E and caspase-3n, and improved brain oxidative stress responses. These findings suggest that a ketone diet has anti-obesity and neuro-protective effects.

Caprylic acid triglyceride is registered as a therapeutic food supplement apparently effective for the treatment of Alzheimer's disease in the United States.[31] Caprylic acid is a middle chain fatty acid (molecular formula $C_8H_{16}O_2$ with eight carbon atoms). The middle chain fatty acid can penetrate blood brain barrier, so it becomes substrate of beta oxidation, which increases the production of the derived ketone body in astrocytes.[32]

Evidence suggests that energy production in the nervous system increases in parallel with symptomatic improvement. In addition, the protection of nerve cells involves adjustments in gene expression, as well as multi-inflammatory, anti-oxidation, and anti-apoptosis mechanisms (later description). β-HB also improves cognitive functions by increasing brain perfusion.

Aging is associated with an increased susceptibility to hypoxic or ischemic damages and a decline in behavioral functions which may be due to attenuated adaptive and/or defense responses.[28] Diet-induced ketosis could improve the behavioral performance of aged rats. For example, old Fischer rats were fed either standard or ketogenic (KG) diets for 3 weeks, and then exposed to hypobaric hypoxia. Cognitive function was measured using the T-maze and object recognition tests. KG diet significantly increased blood ketone levels in both young and old rats. In the aged rats, the KG diet improved cognitive performance under normoxic and hypoxic conditions. Capillary density and HIF-1α levels were elevated in the aged ketonic group, independently of hypoxic challenge. These data suggest that diet-induced ketosis may be beneficial in the treatment of neurodegenerative conditions.

Pharmaceutical Mechanisms of β-HB Action

Inhibition of histone deacetylase: Shimizu et al[33] report that the ketone body β-HB is an endogenous and specific inhibitor of class I histone deacetylases (HDACs). Histone acetylation is a prominent epigenetic modification of the central nervous system that is unequivocally associated with an increase in the rate of gene transcription. Histone acetylation generally favors long-term memory. Histone acetylation is also amenable to pharmacological interventions, predominantly the use of histone deacetylase (HDAC) inhibitors (Figure 3)[34-37] It has therefore spurred considerable interest as a putative target of cognitive enhancement.

Because of the ubiquitous presence of histone acetylation, HDAC inhibitors have great potential not only to treat cognitive impairment resulting from neuro-degenerative disorders, but also to serve as cognitive enhancers for the healthy ones. Gräff and Zsai[34] reviewed the state of the art of HDAC inhibitors used as cognitive treatments or cognitive enhancers. They describe epigenetic priming as a new model for their mode of action, caution against their unsupervised usage, despite their overall great promise.

Recent evidence indicates that the inhibition of histone deacetylase (HDAC) protects the heart against myocardial injury and stimulates endogenous angiomyogenesis, even in the diabetic heart.[35] Sodium butyrate (1%), a specific HDAC inhibitor, was added daily to the drinking water in streptozocin induced diabetic mice to inhibit HDAC activity. HDAC inhibition resulted in a significant functional improvement in STZ-injected diabetic mice. Likewise, HDAC inhibition attenuates cardiac hypertrophy, as evidenced by reduction of heart/tibia ratio and in areas of cardiomyocyte distribution. This was associated with reduced interstitial fibrosis, a decrease in caspase-3 activity and apoptotic histochemical staining, but also with increased angiogenesis in diabetic myocardium. Notably, glucose

Figure 3: Epigenetic activity as inhibitor of histone deacetylases leads to various effects.
Activity as an inhibitor of histone deacetylases leads to various epigenetic modulations, associated with global histone hyperacetylation. Induction of stress response gene FOXO leads to reactive oxygen species detoxification, apoptosis, etc.

transporters (GLUT) 1 and 4 were up-regulated following HDAC inhibition, which was accompanied with increases of GLUT1 acetylation and p38 phosphorylation. Furthermore, myocardial superoxide dismutase, an important antioxidant, was elevated following HDAC inhibition in the diabetic mice.

Class I HDAC inhibition elicits the protection of contractile function following ischemia reperfusion. The study highlights the need for the development of new strategies that target specific HDAC is forms in cardiac insufficiency.[36]

In the heart, the enhancement of lysine acetylation or SUMOylation using HDAC inhibitors or SUMO-1 gene transfer respectively, has been shown to be cardio-protective.[37] The treatment of cardiomyocytes and cardiac fibroblasts with pharmacological inhibitors of HDAC catalytic activity robustly increased the conjugation of SUMO-1 with several high molecular weight proteins in both cardiac cell types. The use of a battery of selective HDAC inhibitors and short hairpin RNAs demonstrated that HDAC2 is the primary HDAC isoform that controls cardiac protein SUMOylation.

Stimulation of FOXO: The fast controls growth hormones, insulin and IGF-1 serves as signals in the transduction system and causes the acetylation of histones in the promoter domain of the FOXO3 gene, inducing the expression of FOXO3.[38] It induces resistance to stress by raising the transcription activity of FOXO.

A transcription factor called FOXO3 is activated at the time of starvation. FOXO3 is able to raise the resistance to oxidation stress and starvation stress. FOXO is a transcription factor belonging to the subgroup "O" of the Forkhead family, interacting DNA-binding domain FOX (Forkhead box) by abbreviation of "Forkhead box O".

In addition, β-HB acts in GPR109A developing in a fat cell and macrophage, which leads to improve arteriosclerosis (Figure 4). The action increases the expression of antioxidant enzymes, such as SOD or catalase, protecting myocardium against oxidation injury.

Resistance to oxidative stress: Concentrations of acetyl-coenzyme A and nicotinamide adenine dinucleotide (NAD (+)) affect histone acetylation and thereby couple cellular metabolic status and transcriptional regulation. The administration of exogenous β-HB, or fasting or calorie restriction, two conditions associated with increased β-HB abundance, all increased global histone acetylation in mouse tissues.[30,33] The inhibition of HDAC by β-HB was correlated with pleiotropic changes in transcription, including transcription of genes encoding oxidative stress resistance factors FOXO3A and MT2. The treatment of cells with β-HB increased histone acetylation at the FOXO3A and Mt2 promoters, and both genes were activated by selective depletion of HDAC1 and HDAC2. Consistent with increased FOXO3A and MT2 activity, the treatment of mice with β-HB conferred substantial protection against oxidative stress.

Protection of mitochondria: It is known that the improvement of the oxidative phosphorylation within mitochondria is important for the cell protection of nerve cells from injury and the reinforcement of cognitive functions. In neuronal energy metabolism, mitochondrial function is important for the treatment of dementia, such as Alzheimer's disease and other

Figure 4: Signal transduction by β-HB by cell surface receptors and activation of genes. Ketone bodies play much more complex roles than merely providing energetic substrates or metabolic intermediates, as they can also act as signaling molecules. Modified from Newman and Verdin.[30]

neurodegenerative diseases.

Zang et al[39] reported that the mechanism whereby β-HB methyl ester (HBME), becoming β-HB of the ketone body by ingestion in the body, protects mitochondria.

Alzheimer's disease (AD) is caused by multiple mechanisms, including a decrease in the cellular utilization of glucose, and mitochondrial alterations in brain cells. HBME inhibits cell apoptosis under conditions of glucose deprivation, and it rescues the activities of mitochondrial respiratory chain complexes that are impaired in AD patients. HBME stabilizes the mitochondrial membrane potential. AD mice treated with HBME demonstrated that HBME has a positive *in vivo* pharmaceutical effect to improve the spatial learning and working memory of mice. A reduction in amyloid-β deposition in mouse brains after intra-gastric administration of HBME was also observed.

When the concentration of blood β-HB was raised between 0.6-1.5 mM in the mice by giving fast and direct β-HB, it was confirmed that the acetylation of histones increases in multiple organs, including the kidney.

Stimulation of adiponectin release: Niacin (nicotinic acid) has recently been shown to increase serum adiponectin concentrations in men with the metabolic syndrome. Since niacin appears to exert its effects on lipolysis through receptor (GPR109A)-dependent and -independent pathways, the role of the identified GPR109A receptor in adiponectin secretion is noteworthy.[40] As niacin administration had no effect on adiponectin and NEFA concentrations in the GPR109A receptor knockout mice, the GPR109A receptor plays an important role in the dual regulation of adiponectin secretion and lipolysis. β-HB has the similar effects on GPR109A receptor.

Suppression of inflammasome: It becomes clear that the inflammasome plays an important role in the onset and the progress of type 2 diabetes, Alzheimer's disease, arteriosclerosis and inflammatory diseases, in addition to a number of autoimmune diseases. The inflammasome activates inflammatory caspase and cytokines of the IL-1 family within a complex of proteins involved in inflammation and apoptosis.[38] The inflammasome has been seen as a natural immunity system that protects living organisms against alien substances and pathogenic microorganisms.

Prolonged fasting reduces inflammation. However, we do not know what effect on the innate immune response result from ketones, and other alternative metabolic fuels produced during energy deficits. β-HB, contrary to AcAc and the structurally related butyrate and acetate, suppresses the activation of the NLRP3 inflammasome in response to urate crystals, ATP and lipotoxic fatty acids. Mechanistically, β-HB inhibits the NLRP3 inflammasome by preventing K (+) efflux and by reducing ASC oligomerization. The inhibitory effects of β-HB on NLRP3 are not dependent on chirality or starvation-regulated mechanisms like AMP-activated protein kinase (AMPK), reactive oxygen species (ROS), autophagy or glycolytic inhibition. β-HB reduces NLRP3 inflammasome-mediated interleukin IL-1β and IL-18 production in human monocytes. The anti-inflammatory effects of caloric restriction or ketogenic diets may be linked to β-HB-mediated inhibition of the NLRP3 inflammasome.[41]

FUTURE PROBLEM

A new therapeutic approach could merge for the treatment of cancer.[42-47] Metformin is usually used for the treatment of type 2 diabetes. Recently, metformin, vitamin D and ketone in combination showed broad-spectrum antitumor activities.[48] In combination, metformin and vitamin D exhibited synergistic effects on cancer cell proliferation and apoptosis. The underlying anti-tumor mechanisms may involve m-TOR related pathways, which are related to activating expression of cleaved caspase-3, Bax and p-AMPK.

However, many problems remain. Humans have no experience to delete carbohydrate from meal at all, and high protein and lipid intake should be inevitable to compensate total energy expenditure. The balance of these effects should be studied, but notably original ketogenic diet for epilepsy by Russel Wilder in 1920 contained nearly 90% fat. High protein diet is a risk factor of cardiovascular diseases, renal insufficiency and cancer.[49] So, the balance of risk and benefits should be considered.[50]

Finally, the interaction with intestinal microbiota should be clarified. We have previously hypothesized that *bifidobacterium* contribute to produce β-HB.[5] There are many bacteria that can synthesize poly(3-hydroxy butyrate-co-3 hydroxyvalerate) oly-beta hydroxyl butyrate.[51] These bacteria are capable of using a broad range of carbon sources for their growth and for the production of polyhydroxyalkanoates (PHAs). They can use monosaccharides (glucose and fructose), disaccharides (sucrose), pentoses (xylose and arabinose), various organic acids (acetic acid, propionic acid and octanoic acid) and even the acid pre-treated liquor (APL) of sugarcane trash, a lignocellulosic biomass, for growth and the production of polyhydroxyalkanoates (PHAs).

The contribution of intestinal microbiota to ketone body production should open a new field of medicine.

ACKNOWLEDGEMENT

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflicts of interest.

REFERENCES

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care*. 2009; 32(7): 1335-1343. doi: 10.2337/dc09-9032

2. Cahill GF Jr. Fuel metabolism in starvation. *Ann Rev Nutr*. 2006; 26: 1-22. doi: 10.1146/annurev.nutr.26.061505.111258

3. Cahill GF Jr, Veechi RL. Ketoacids? Good medicine? *Trans Am Clin Climatol Assoc*. 2003; 114: 149-163.

4. Laffel L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. *Diabetes Metab Res Rev*. 1999; 15(6): 412-426. doi: 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8

5. Hirakawa A, Watanabe S, Tanaka S. Koda's fasting therapy: Energy balance and intestinal bacterial flora. *Adv Food Technol Nutr Sci Open J*. 2015; 1(5): 112-123. doi: 10.17140/AFTNSOJ-1-120

6. Blazques C, Woods A, de Ceballos ML, Carling D, Guzman M. The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes. *J Neurochem*. 1999; 73(4): 1674-1682. doi: 10.1046/j.1471-4159.1999.731674.x

7. Koda M. Science of the fasting therapy. Practical improvement of constitution. Osaka, Japan: Shun-ju-sha; 1980.

8. NIH, The National Institute of Diabetes and Digestive and Kidney Diseases. Gestational diabetes. 2014. Web site. https://www.niddk.nih.gov/health-information/diabetes/types/gestational. Accessed June 28, 2016

9. Ogushi Y, Hanaki Y, Muneta T, Douya H, Yamauchi T. Zero saccharide diet research group. *Japan Society for Lipid Nutrition*. 2010; 19(1): 53-58.

10. Shambaugh GE 3rd. Ketone body metabolism in the mother and fetus. *Fed Proc*. 1985; 44(7): 2347-2351.

11. Watanabe S. People's physician. Angel for mothers. Muneta Maternal Clinic. *Clin Funct Nutr*. 2016; 8(4): 159-162.

12. Krempaský M, Maskaľová I, Bujňák L, Vajda V. Ketone bodies in blood of dairy cows: Prevalence and monitoring of subclinical ketosis. *Acta Vet Brno*. 2014, 83: 411-416. doi: 10.2754/avb201483040411

13. Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interation with PPAR alpha and transcription at the Hmgcs 2 PPRE. *FASEB J*. 2010; 24(6): 1914-1924. doi: 10.1096/fj.09-149765

14. Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-

CoA synthase: A control enzyme in ketogenesis. *Biochem J*. 1999; 338(Pt3): 569-582. doi: 10.1042/bj3380569

15. Urich K. Ketone body formation and degradation. In: *Comparative Animal Biochemistry*. Berlin, Germany: Springer-Verlag; 1993: 579-580.

16. Partsalaki I, Karvela A, Spiliotis BE. Metabolic impact of a ketogenic diet compared to a hypocaloric diet in obese children and adolescents. *J Pediatr Endocrinol Metab*. 2012; 25(7-8): 697-704. Web site. http://www.degruyter.com/view/j/jpem.2012.25.issue-7-8/jpem-2012-0131/jpem-2012-0131.xml. Accessed June 28, 2016

17. Bender DA, Mayer PA. Glycolysis & the oxidation of pyruvate. In: Murray RK, Bender AD, Botham KM, et al, eds. *Harper's Illustrated Biochemistry*. 29th ed. Lange, NY, USA: McGraw Hill Professional; 2012: 170-177.

18. Wilder RM, Winter MD. The threshold of ketogenesis. *J Biol Chem*. 1922; 52: 393-401. Web site. http://www.jbc.org/content/52/2/393.short. Accessed June 28, 2016

19. Kossoff EH. Zupec-Kanici BA, Amask PE, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. *Epilepsia*. 2009; 50(2): 304-317. doi: 10.1111/j.1528-1167.2008.01765.x

20. Cervenka MC, Henry BJ, Felton EA, Patton K, Kossoff EH. Establishing an adult epilepsy diet center: Experience, efficacy and challenges. *Epilepsy Behav*. 2016; 58: 61-68. doi: 10.1016/j.yebeh.2016.02

21. Mosek A, Natour H, Neufeld MY, Shiff Y, Vaisman N. Ketogenic diet treatment in adults with refractory epilepsy: A prospective pilot study. *Seizur*. 2009; 18(1): 30-33. doi: 10.1016/j.seizure.2008.06.001

22. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. *J Child Neurol*. 2003; 18(2): 113-118. doi: 10.1177/08830738030180020501

23. Chen Y, Du J, Zhao YT, et al. Histone deacetylase (HDAC) in hibition improves myocardial function and prevents cardiac remodeling in diabetic mice. *Cardiovasc Diabetol*. 2015; 14: 1-99. doi: 101186/512933-015-0262-8

24. Zou Z, Sasaguri S, Rajesh KG, Suzuki R. dl-3-Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts. *Am J Physiol Heart Circ Physiol*. 2002; 283(5): H1968-H1974. doi: 10.1152/ajpheart.00250.2002

25. Honda H, Sasaki K, Hamasaki H, et al. Trends in autopsy-

verified dementia prevalence over 29 years of the Hisayama study. *Neuropathology*. 2016; 36(4): 383-387. doi: 10.1111/neup.12298

26. Matsuzaki T1, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. *Neurology*. 2010; 75(9): 764-770. doi: 10.1212/WNL.0b013e3181eee25f

27. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. *Prostaglandins Leukot Essent Fatty Acids*. 2004; 70(3): 309-319. doi: 10.1016/j.plefa.2003.09.007

28. Xu K, Sun X, Eroku BO, Tsipis CP, Puchowicz MA, LaManna JC. Diet-induced ketosis improves cognitive performance in aged rats. *Adv Exp Med Biol*. 2010; 662: 71-75. doi: 10.1007/978-1-4419-1241-1_9

29. Mohamed HE, El-Swefy SE, Rashed LA, Abd El-Latif SK. Biochemical effect of a ketogenic diet on the brains of obese adult rats. *J Clin Neurosci*. 2010; 17(7): 899-904. doi: 10.1016/j.jocn.2009.11.005

30. Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. *Diabetes Res Clin Practice*. 2014; 106(2): 173-181. doi: 10.1016/j.diabres.2014.08.009

31. Arzheimer's association. Capric acid. Web site. http://www.alz.org/alzheimers_disease_alternative_treatments.asp. Accessed June 28, 2016

32. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: Two case reports. *J Am Coll Nutr*. 1995; 14(2): 202-208. doi: 10.1080/07315724.1995.10718495

33. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. *Science*. 2013; 339(6116): 211-214. doi: 10.1126/science.1227166

34. Gräff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. *Annu Rev Pharmacol Toxicol*. 2013; 53: 311-330. doi: 10.1146/annurev-pharmtox-011112-140216

35. Chen Y, Du J, Zhao YT, et al. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. *Cardiovasc Diabetol*. 2015; 14: 99. doi: 10.1186/s12933-015-0262-8

36. Aune SE, Herr DJ, Mani SK, Menick DR. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion. *J Mol Cell Cardiol*. 2014; 72: 138-145. doi: 10.1016/j.yjmcc.2014.03.005

37. Blakeslee WW, Wysoczynski CL, Fritz KS, Nyborg JK, Churchill ME, McKinsey TA. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. *Cell Signal*. 2014; 26(12): 2912-2220. doi: 10.1016/j.cellsig.2014.09.005

38. Edwards C, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-hydroxybutyrate extends lifespan in C. elegans. *Aging (Albany NY)*. 2014; 6(8): 621-644. doi: 10.18632/aging.100683

39. Zhang J, Cao Q, Li S, et al. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism. *Biomaterials*. 2013; 34(30): 7552-7562. doi: 10.1016/j.biomaterials.2013.06.043

40. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. *Am J Physiol Endocrinol Metab*. 2009; 296(3): E549-58. doi: 10.1152/ajpendo.91004.200841

41. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med*. 2015; 21(3): 263-269. doi: 10.1038/nm.3804

42. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostine DP. Ketone supplementation decreases tumor cell vaiability and prolongs survival of mice with metastatic cancer. *Int J Cancer*. 2014; 135(7): 1711-1720. doi: 10.1002/ijc.28809

43. Shukla SK, Gebegiworgis T, Purohit V, et al. Metabolic reprograming induced by ketone bodies diminishes pancreatic cachexia. *Cancer Metab*. 2014; 2: 18. doi: 10.1186/2049-3002-2-18

44. Oleksyszyn J. The complete control of glucose level utilizing the composition of ketoenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug methormin, as a potential anti-cancer therapy. *Med Hypotheses*. 2011; 77(2): 171-173. doi: 10.1016/j.mehy.2011.04.001

45. Maurer GD, Brucker DP, Bahr O, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: A rationale for ketogenic diet as experimental glioma therapy. *BMC Cancer*. 2011; 11: 315. doi: 10.1186/1471-2407-11-315

46. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that cancer cells use oxidative mitochondrial metabolism. *Cell cycle*. 2010; 9(17): 3506-3514. doi: 10.4161/cc.9.17.12731

47. Adbelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. *PLoS One*. 2012; 7(5): e36197. doi:

10.1371/journal.pone.0036197

48. Guo LS, Li HX, Li CY, et al. Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways. *Pharmazie*. 2015; 70(2): 117-122. doi: 10.1691/ph.2015.4535

49. Watanabe S. Cardiovascular risk of high protein diet. *Clin Funct Nutr*. 2012; 4(4): 186-191.

50. Hirakawa A, Melby MK, Watanabe S. Comprehensive food labeling for obesity control. *Adv Obes Weight Manag Control*. 2016; 4(3): 00088. doi: 10.15406/aowmc.2016.04.00088

51. Moorkoth D, Nampoothiri KM. Production and characterization of poly (3-hydroxy butyrate-co-3 hydroxyvalerate) (PHBV) by a novel halotolerant mangrove isolate. *Bioresour Technol*. 2016; 201: 253-260. doi: 10.1016/j.biortech.2015.11.046